- $14.80m
- $13.15m
- $22.10m
- 57
- 51
- 22
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.22 | ||
| Price to Tang. Book | 2.22 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.67 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -45% | ||
| Return on Equity | -47.63% | ||
| Operating Margin | -15.51% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 37.68 | 21.36 | 24.91 | 25.24 | 22.1 | n/a | n/a | -12.33% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -66.23 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The Company markets its corporate drug testing services through its own sales force, distributors, and partners. It markets its home drug testing service, PDT-90, through the Internet.
Directors
- Raymond Kubacki CHM (76)
- Charles Doucot EVP (55)
- Michael Schaffer VOP (76)
- Andrew Limbek VPR (35)
- Harry Connick IND (95)
- Robyn Davis IND (60)
- Walter Tomenson IND (74)
- Fred Weinert IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 24th, 1986
- Public Since
- January 22nd, 1987
- No. of Shareholders
- 146
- No. of Employees
- 116
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 5,805,611
- Address
- 125 Nagog Park Ste 200, ACTON, 01720-3451
- Web
- https://www.psychemedics.com/
- Phone
- +1 9782068220
- Auditors
- BDO USA, LLP
Upcoming Events for PMD
Q2 2024 Psychemedics Corp Earnings Release
Psychemedics Corp Annual Shareholders Meeting
Similar to PMD
ADVANCED BIOMED
NASDAQ Capital Market
Aesthetic Medical International Holdings
NASDAQ Capital Market
Akanda
NASDAQ Capital Market
American Oncology Network
NASDAQ Capital Market
Assure Holdings
NASDAQ Capital Market
FAQ
What is the Psychemedics share price?
As of Today at 19:17 UTC, shares in Psychemedics are trading at $2.55. This share price information is delayed by 15 minutes.
How has the Psychemedics share price performed this year?
Shares in Psychemedics last closed at $2.55 and the price had moved by -53.72% over the past 365 days. In terms of relative price strength the Psychemedics share price has underperformed the S&P500 Index by -62.67% over the past year.
What are the analyst and broker recommendations for Psychemedics?
There is no consensus recommendation for this security.
What is the Psychemedics dividend yield?
Psychemedics does not currently pay a dividend.
Does Psychemedics pay a dividend?
Psychemedics does not currently pay a dividend.
When does Psychemedics next pay dividends?
Psychemedics does not currently pay a dividend.
How do I buy Psychemedics shares?
To buy shares in Psychemedics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Psychemedics?
As of the previous close price of $2.55, shares in Psychemedics had a market capitalisation of $14.80m.
Where are Psychemedics shares listed?
Here are the trading details for Psychemedics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PMD
What kind of share is Psychemedics?
Based on an overall assessment of its quality, value and momentum Psychemedics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Psychemedics share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Psychemedics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Psychemedics. Over the past six months, its share price has underperformed the S&P500 Index by -7.61%.
As of the last closing price of $2.55, shares in Psychemedics were trading -22.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Psychemedics PE Ratio?
The Psychemedics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.55.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Psychemedics?
Psychemedics' management team is headed by:
- Raymond Kubacki - CHM
- Charles Doucot - EVP
- Michael Schaffer - VOP
- Andrew Limbek - VPR
- Harry Connick - IND
- Robyn Davis - IND
- Walter Tomenson - IND
- Fred Weinert - IND